Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs). Discover the innovative approaches to nasal sprays, and learn about the significant strides being made in transitioning to environmentally friendly, low-global warming potential (GWP) propellants in pressurized metered-dose inhalers (pMDIs). Nanopharm’s commitment to advancing pharmaceutical technologies and delivering client-focused solutions is at the forefront of Rob’s discussion.

Articles
Intranasal Oligonucleotide Delivery: Nanopharm & Aptar Pharma Data
Nanopharm and Aptar Pharma present new data at IPAC-RS NIF 2026 proving Antisense Oligonucleotide (ASO) biologics can be nasally delivered intact